Meeting
2013 Breast Cancer Symposium
21-gene recurrence score testing and subsequent treatment decisions in patients (pts) with estrogen-receptor–positive (ER+) early-stage breast cancer (ESBC).
Authors
Jennifer B. Manders
The Christ Hospital, Cincinnati, OH
Jennifer B. Manders , Joan Burkhart , Debra Campbell , James J. Devitt , Judith Vacchino , Amy Pratt Sing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A
Track
Local/Regional Therapy,Risk Assessment, Prevention, Detection, and Screening
Sub Track
Genomics
Citation
J Clin Oncol 31, 2013 (suppl 26; abstr 30)
DOI
10.1200/jco.2013.31.26_suppl.30
Abstract #
30
Poster Bd #
C12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
First Author: Jenny Jimmy Hong
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Artificial intelligence-assisted evaluation of tumor infiltrating CD3+ and CD8+ T cells for prognostication and prediction of benefit from adjuvant chemotherapy in early stage colorectal cancer (CRC): A retrospective analysis of the QUASAR trial.
First Author: Christopher Williams
Poster
2022 ASCO Annual Meeting
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
First Author: Lifen Cao